



US008815858B2

(12) **United States Patent**
Bjornson et al.

(10) **Patent No.:** **US 8,815,858 B2**
(45) **Date of Patent:** **Aug. 26, 2014**

(54) **HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS**

(75) Inventors: **Kyla Bjornson**, San Mateo, CA (US); **Steven S. Bondy**, Danville, CA (US); **You-chul Choi**, Foster City, CA (US); **Chien-Hung Chou**, Livermore, CA (US); **Ruchika Mishra**, San Jose, CA (US); **James D. Trenkle**, Oakland, CA (US); **Winston C. Tse**, Redwood City, CA (US); **Randall W. Vivian**, San Mateo, CA (US); **James G. Taylor**, San Mateo, CA (US)

(73) Assignee: **Gilead Sciences, Inc.**, Foster City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/699,142**

(22) PCT Filed: **May 20, 2011**

(86) PCT No.: **PCT/US2011/037305**

§ 371 (c)(1),
(2), (4) Date: **Mar. 6, 2013**

(87) PCT Pub. No.: **WO2011/146817**

PCT Pub. Date: **Nov. 24, 2011**

(65) **Prior Publication Data**

US 2013/0171102 A1 Jul. 4, 2013

Related U.S. Application Data

(60) Provisional application No. 61/347,215, filed on May 21, 2010.

(51) **Int. Cl.**

A61K 31/50 (2006.01)
A61K 31/497 (2006.01)
A61K 31/519 (2006.01)
A61K 38/21 (2006.01)
C07D 487/00 (2006.01)
C07D 409/00 (2006.01)

(52) **U.S. Cl.**

USPC **514/248**; 514/252.02; 514/265.1;
424/85.4; 544/236; 544/238; 544/280

(58) **Field of Classification Search**

USPC 514/248, 252.02, 265.1; 424/85.4;
544/236, 238, 280

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,996,206 A 2/1991 Taylor et al.
5,248,775 A 9/1993 Taylor et al.
5,726,302 A * 3/1998 Ugarkar et al. 536/27.13
7,648,998 B2 1/2010 Bondy et al.
8,232,278 B2 7/2012 De Jonghe et al.

8,338,435 B2 12/2012 Herdewijn et al.
2006/0052602 A1 3/2006 Kim et al.
2006/0252791 A1 11/2006 Bondy et al.
2007/0724418 * 10/2007 Leuven et al. 514/300
2008/0182870 A1 7/2008 Bondy et al.
2008/0207678 A1* 8/2008 Bondy et al. 514/300
2009/0226398 A1* 9/2009 Leivers et al. 424/85.4
2009/0285782 A1 11/2009 Gao et al.
2010/0143299 A1 6/2010 Gao et al.
2010/0305117 A1 12/2010 Herdewijn et al.

FOREIGN PATENT DOCUMENTS

WO WO-2004/005286 A2 1/2004
WO WO-2005/063744 A2 7/2005
WO WO-2006/033703 A1 3/2006
WO WO-2008/005519 A2 1/2008
WO WO-2008/133669 A2 11/2008
WO WO-2009/009001 A1 1/2009
WO WO-2009/111501 A1 9/2009

OTHER PUBLICATIONS


Boyer et al., "Pathogenesis, diagnosis and management of hepatitis C," J Hepatol. 32(1 Suppl):98-112 (2000).
Calisher et al., "Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera," J Gen Virol. 70(Pt 1):37-43 (1989).
Di Bisceglie et al., "The unmet challenges of hepatitis C," Sci Am. 281(4):80-85 (1999).
Domingo et al., "The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance—a review," Gene. 40(1):1-8 (1985).
Dymock et al., "Novel approaches to the treatment of hepatitis C virus infection," Antivir Chem Chemother. 11(2):79-96 (2000).
Fukumoto et al., "Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions," Hepatology. 24(6):1351-1354 (1996).
Gordon et al., "Control of hepatitis C: a medicinal chemistry perspective," J Med Chem. 48(1):1-20 (2005).
International Search Report for International Application No. PCT/US2011/037305, mailed Aug. 18, 2011 (5 pages).
Martell et al., "Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution," J Virol. 66(5):3225-3229 (1992).
Moennig et al., "The pestiviruses," Adv Virus Res. 41:53-98 (1992).
Moradpour et al., "Replication of hepatitis C virus," Nat Rev Microbiol. 5(6):453-463 (2007).
Nasakin et al., "Reactions of 3,3,4,4-tetracyanopyrrolidines with alcohols," Chemistry of Heterocyclic Compounds 28(11):1255-1259 (1992).

(Continued)

Primary Examiner — Raymond Henley, III
(74) Attorney, Agent, or Firm — Clark & Elbing LLP

(57) **ABSTRACT**

The invention is related to anti-viral compounds of formula (A) as defined in the claims, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well to processes and intermediates useful for preparing such compounds.



(A)

40 Claims, No Drawings